北芯生命：专注心血管精准介入领域 用创新和品质改善生命健康——深圳北芯生命科技股份有限公司首次公开发行股票并在科创板上市网上投资者交流会精彩回放

Core Viewpoint - The company focuses on innovative medical devices for precise cardiovascular diagnosis and treatment, aiming to improve health outcomes through quality and innovation [1] Business Overview - The company specializes in the research, development, production, and sales of innovative medical devices for cardiovascular diseases, addressing clinical needs in areas such as coronary artery disease, peripheral vascular disease, and atrial fibrillation [1] - As of September 30, 2025, the company has launched 11 products and has 6 products in development, covering five major categories including IVUS systems and FFR systems [2] Operational Performance - The core product, the FFR system, captured 30.6% of the domestic market share in 2021, with over 70% of its usage in tertiary hospitals across 30 provinces in China and clinical applications in over 1,000 hospitals globally [3] - The IVUS system is the first domestically developed 60MHz high-definition product approved by the National Medical Products Administration, achieving a market share of 10.4% in the coronary disease sector by 2024 [3] Research and Development - The company has established four core technology platforms to support continuous innovation in cardiovascular medical devices, resulting in 25 Class III medical device registrations and 185 patents as of June 30, 2025 [4] - The R&D team consists of 100 members, with over 40% holding advanced degrees, ensuring a strong foundation for long-term development [9] Financial Performance - The company's revenue for the periods from 2022 to 2025 is projected to grow significantly, with expected net profits for 2025 ranging from 78 million to 88 million yuan, representing a growth of 278.91% to 301.85% year-on-year [6] - The gross profit margins for the same periods are reported at 63.50%, 65.02%, 63.32%, and 69.06%, indicating stable margins due to increased production scale [7] Industry Context - The cardiovascular disease market in China is rapidly growing, with PCI procedures being the main application for the company's products, although the penetration rate remains lower than in developed countries [12] - Future trends indicate an increase in PCI penetration, a shift towards high-end active intervention devices, and a growing emphasis on integrated diagnostic solutions [13] Competitive Advantages - The company emphasizes its focus on precise cardiovascular solutions, strong independent R&D capabilities, and a well-established commercialization network, positioning itself favorably in the market [11] Funding and Investment - The company plans to raise approximately 952.21 million yuan through its public offering, with funds allocated for the construction of a medical device industrialization base and R&D projects [19][20][21]